Actively Recruiting
Sensor-based Congestion Alert for Events in Peritoneal Dialysis (SCALE-PD)
Led by Bodyport Inc. · Updated on 2026-03-18
125
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to explore how the Bodyport Cardiac Scale can predict worsening health events caused by fluid overload in people with kidney disease who are receiving peritoneal dialysis. The study focuses on measuring hemodynamic biomarkers, including individual signals and combined scores like the Congestion Index and a novel PD Index, to better understand fluid status in these patients. Participants will use the Bodyport Cardiac Scale device, which captures multiple physiological signals related to heart and fluid status. The study involves patients with end-stage kidney disease treated with automated peritoneal dialysis and monitored via the Vantive Sharesource Remote Patient Management Platform. The study does not involve changes to treatment but observes biomarker data over time. During the study, participants will be monitored for up to one year to evaluate the sensitivity of biomarker measurements in predicting fluid overload events. Researchers will assess dialysis-related events and track physiological signals from the device. Participants must be able to stand unassisted and will be involved in ongoing data collection without altering their usual care.
CONDITIONS
Brief Title
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 21 years or older
- Able to speak and read English, or speak and read Spanish with caregiver assistance
- Able to stand on two bare feet without help
- Receiving automated peritoneal dialysis for end-stage kidney disease
- Followed on the Vantive Sharesource Remote Patient Management Platform
You will not qualify if you...
- Undergoing or planning hemodialysis within the next 12 months
- Life expectancy less than 12 months
- Pregnant or planning pregnancy within the next 12 months
- Weighs more than 375 pounds
- Planned kidney transplant within the next 12 months
- Has an implanted neurostimulator system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 year
Participants with kidney disease on peritoneal dialysis are observed using the Bodyport Cardiac Scale to measure hemodynamic biomarkers and fluid status.
Regular measurements using the Bodyport Cardiac Scale as part of monitoring
Trial Site Locations
Total: 4 locations
1
Desert Cities Dialysis
Victorville, California, United States, 92395
Actively Recruiting
2
Southeastern Clinical Research Institute
Augusta, Georgia, United States, 30904
Actively Recruiting
3
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
4
Seven Oaks General Hospital
Winnipeg, Manitoba, Canada, R2V 3M3
Actively Recruiting
Research Team
C
Corey Centen
D
Dorothy Kwok
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here